5-Amino-1MQ — NNMT inhibition, dose, and what actually happened
31 posts
5-Amino-1MQ is an NNMT inhibitor (nicotinamide N-methyltransferase). In theory inhibiting NNMT should spare SAM and NAD+ precursors and improve metabolic phenotype in adipose.
Ran 150 mg/day oral, 12 weeks. Body comp moved a little (probably within noise), energy subjectively good, labs didn't shift much. Is anyone running a higher dose or seeing clearer signal?
7 Replies
205 posts
150 mg is on the lower end of what people describe as effective. The 250-300 mg range shows up more often in the positive writeups. Whether that's a real dose-response or selection bias I genuinely don't know.
- CJC-1295 no DAC · 100 mcg · pre-bed · sub-Q
- Ipamorelin · 200 mcg · pre-bed · sub-Q
- BPC-157 · 500 mcg · 2x/day · sub-Q
115 posts
The NNMT inhibition story is well-supported mechanistically. The human-scale effect in healthy adults has basically no published data. In the rodent work the phenotype in obese models is clearer than in lean models, which might explain why your labs moved less than the marketing suggests.
34 posts
The 'fat loss peptide' framing in vendor marketing is ahead of the evidence. In obese rodents, yes. In lean humans, mostly no data. Don't expect dramatic body comp results at any dose if your starting phenotype isn't metabolically compromised.
31 posts
ApoB didn't move for me on 250 mg x 8 weeks either. The lipid story for 5-Amino is overstated in the bro-science writeups.
31 posts
Appreciating the reality check. Was going to bump to 300 — might pilot that for a 6-week block and report back.